Effects of azithromycin and doxycycline on the vaginal microbiota of women with urogenital Chlamydia trachomatis infection: a substudy of the Chlazidoxy randomized controlled trial
- PMID: 37100225
- DOI: 10.1016/j.cmi.2023.04.020
Effects of azithromycin and doxycycline on the vaginal microbiota of women with urogenital Chlamydia trachomatis infection: a substudy of the Chlazidoxy randomized controlled trial
Abstract
Objectives: Dysbiotic bacterial communities within the vagina are associated with Chlamydia trachomatis infection. We compared the effect of treatment with azithromycin and doxycycline on the vaginal microbiota in a cohort of women with a urogenital C. trachomatis infection randomly assigned to one of these treatments (Chlazidoxy trial).
Methods: We analysed vaginal samples from 284 women (135 in the azithromycin group and 149 in the doxycycline group) collected at baseline and 6 weeks after treatment initiation. The vaginal microbiota was characterized using 16S rRNA gene sequencing and classified into community state types (CSTs).
Results: At baseline, 75% (212/284) of the women had a high-risk microbiota (CST-III or CST-IV). A cross-sectional comparison 6 weeks after treatment showed that 15 phylotypes were differentially abundant, but this difference was not reflected at the CST (p 0.772) or diversity level (p 0.339). Between baseline and the 6-week visit, α-diversity (p 0.140) and transition probabilities between CSTs were not significantly different between the groups, and no phylotype was differentially abundant.
Discussion: In women with urogenital C. trachomatis infection, the vaginal microbiota does not seem to be affected by azithromycin or doxycycline 6 weeks after treatment. Because the vaginal microbiota remains susceptible to C. trachomatis infection (with CST-III or CST-IV) after antibiotic treatment, women remain at risk of reinfection, which could originate from unprotected sexual intercourse or untreated anorectal C. trachomatis infection. This last consideration advocates for the use of doxycycline instead of azithromycin because of its higher anorectal microbiological cure rate.
Keywords: 16S rRNA gene sequencing; Antibiotics; Chlamydia trachomatis treatment; Community state types; Vaginal microbiome.
Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Randomized, open-label, multicenter study of azithromycin compared with doxycycline for treating anorectal Chlamydia trachomatis infection concomitant to a vaginal infection (CHLAZIDOXY study).Medicine (Baltimore). 2019 Feb;98(7):e14572. doi: 10.1097/MD.0000000000014572. Medicine (Baltimore). 2019. PMID: 30762806 Free PMC article. Clinical Trial.
-
Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial.Lancet Infect Dis. 2022 Aug;22(8):1221-1230. doi: 10.1016/S1473-3099(22)00148-7. Epub 2022 May 9. Lancet Infect Dis. 2022. PMID: 35550262 Clinical Trial.
-
Nonoptimal Vaginal Microbiota After Azithromycin Treatment for Chlamydia trachomatis Infection.J Infect Dis. 2020 Feb 3;221(4):627-635. doi: 10.1093/infdis/jiz499. J Infect Dis. 2020. PMID: 31573603 Free PMC article.
-
Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women.Cochrane Database Syst Rev. 2019 Jan 25;1(1):CD010871. doi: 10.1002/14651858.CD010871.pub2. Cochrane Database Syst Rev. 2019. PMID: 30682211 Free PMC article.
-
Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women.Pharmacoeconomics. 1997 Nov;12(5):596-611. doi: 10.2165/00019053-199712050-00010. Pharmacoeconomics. 1997. PMID: 10174326 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical